Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14975188 | 0.88 | NAAA (0.47) | FAAHSMN1; SMN2ALDH1A1GAACES1 | |
| SCHEMBL14974894 | 0.75 | LMNA (0.48) | SMN1; SMN2ALDH1A1GAACES1NAAA | |
| SCHEMBL14975406 | 0.75 | LMNA (0.48) | SMN1; SMN2ALDH1A1GAACES1NAAA | |
| SCHEMBL14975262 | 0.75 | LMNA (0.48) | SMN1; SMN2ALDH1A1GAACES1NAAA | |
| SCHEMBL29184630 | 0.72 | KMT2A (0.53) | FAAHALDH1A1GAACES1 | |
| SCHEMBL17556993 | 0.72 | FAAH (0.41) | FAAHPTGESALOX5PPARG | |
| SCHEMBL14975361 | 0.71 | HCAR2 (0.46) | SMN1; SMN2PSMB5ALDH1A1GAAALOX5 | |
| SCHEMBL25065426 | 0.71 | FAAH (0.49) | FAAHALDH1A1 | |
| SCHEMBL22922952 | 0.71 | FAAH (0.49) | FAAHALDH1A1 | |
| SCHEMBL17556994 | 0.70 | FAAH (0.41) | FAAHPTGESALOX5PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2782567-B1 | DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) | UNIV CALIFORNIA (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160235707-A1 | DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) | FOND ST ITALIANO TECNOLOGIA (IT) | 2016-08-18 | — | — | US | disclosed |
| US-9353075-B2 | Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2782567-A1 | DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) | The Regents of The University of California (US) | 2014-10-01 | — | — | EP | disclosed |
| US-20130281490-A1 | Disubstituted Beta-lactones as Inhibitors of N-Acylethanolamine Acid Amidase (NAAA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-10-24 | — | — | US | disclosed |
| WO-2013078430-A1 | DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281490-A1 | Disubstituted Beta-lactones as Inhibitors of N-Acylethanolamine Acid Amidase (NAAA) | NAAA, FAAH, FAAH2 | FAAH 2/4885SMN1; SMN2 3405/4885PSMB5 1414/4885 |
| US-20160235707-A1 | DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) | NAAA, FAAH, FAAH2 | FAAH 2/4885SMN1; SMN2 3405/4885PSMB5 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.